Mays Erin M, Dorman David C, McKendry Colleen, Hanel Rita M
Departments of Clinical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, NC 27695 (Mays, Daorman, Hanel), and.
Department of Statistics, NCSU Bioinformatics Research Center, NCSU College of Physical and Mathematical Sciences, Raleigh, NC, 27607 (McKendry).
J Vet Emerg Crit Care (San Antonio). 2018 Nov;28(6):518-526. doi: 10.1111/vec.12778. Epub 2018 Oct 10.
To document if a transient hypercoagulable state occurs in healthy dogs following abrupt cessation of unfractionated heparin (UFH) therapy.
Prospective experimental pilot study.
University research facility.
Seven adult random-source male dogs.
Thromboelastography (TEG) and thrombin-antithrombin (TAT) complex formation were used to assess coagulation status in healthy dogs. Seven adult research dogs received 200-300 IU/kg subcutaneous UFH every 8 hours for 4 days. A final IV bolus of 100 IU/kg was given on day 4 and the peak measured heparin concentration 1 hour later is defined as the start of heparin withdrawal (time 0). Citrated whole blood samples were collected at baseline (prior to heparin administration) and 3, 6, 12, 30, and 48 hours after UFH withdrawal. At all time points, a kaolin-activated TEG was performed and citrated plasma for measurement of TAT concentration was collected for batch analysis. Fibrinogen concentration, PCV, total plasma proteins, and platelet count were measured at baseline and 48 hours after heparin withdrawal.
Compared to baseline, TAT was increased 12 hours after heparin withdrawal and returned to baseline by 30 hours. TEG clot formation time (K) was decreased 30 and 48 hours after heparin withdrawal.
TAT results suggest that a transient increase in thrombin generation developed 12 hours after withdrawal of UFH therapy. Though clot kinetics were rapid compared to baseline beginning 30 hours after heparin withdrawal, a return to baseline was not documented. Future studies are warranted to determine the clinical relevance of these results and to evaluate the effect of UFH withdrawal in critically ill animals.
记录健康犬在普通肝素(UFH)治疗突然停止后是否会出现短暂的高凝状态。
前瞻性实验性初步研究。
大学研究机构。
7只成年随机来源的雄性犬。
采用血栓弹力图(TEG)和凝血酶 - 抗凝血酶(TAT)复合物形成来评估健康犬的凝血状态。7只成年研究犬每8小时皮下注射200 - 300 IU/kg的UFH,持续4天。在第4天给予100 IU/kg的静脉推注,1小时后测得的肝素峰值浓度定义为肝素撤药开始时间(时间0)。在基线(肝素给药前)以及UFH撤药后3、6、12、30和48小时采集枸橼酸化全血样本。在所有时间点,进行高岭土激活的TEG检测,并采集枸橼酸化血浆用于批量分析TAT浓度。在基线和肝素撤药后48小时测量纤维蛋白原浓度、红细胞压积、总血浆蛋白和血小板计数。
与基线相比,肝素撤药后12小时TAT升高,30小时恢复至基线。肝素撤药后30和48小时TEG凝血形成时间(K)缩短。
TAT结果表明,UFH治疗撤药后12小时凝血酶生成出现短暂增加。尽管肝素撤药30小时后与基线相比凝血动力学较快,但未记录到恢复至基线水平。有必要进行进一步研究以确定这些结果的临床相关性,并评估UFH撤药对危重病动物的影响。